AG2R LA Mondiale Gestion D Actifs Acquires New Shares in Zoetis Inc. $ZTS

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired 17,178 shares of Zoetis Inc. for approximately $2.9 million as part of its first-quarter investments.
• In the same quarter, multiple hedge funds, including Nuveen LLC and Mackenzie Financial Corp, made substantial investments in Zoetis, with 92.80% of the stock now owned by institutional investors.
• Zoetis recently reported $1.76 EPS for the quarter, exceeding expectations, while analysts have mixed ratings on the stock with a consensus target price of $200.88.

AG2R LA Mondiale Gestion D Actifs acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 17,178 shares of the company's stock, valued at approximately $2,897,000.

Several other hedge funds have also recently bought and sold shares of ZTS. Nuveen LLC purchased a new position in Zoetis in the 1st quarter valued at approximately $616,375,000. Sarasin & Partners LLP purchased a new position in Zoetis in the 1st quarter valued at approximately $339,111,000. Mackenzie Financial Corp increased its stake in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. GAMMA Investing LLC increased its stake in Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after purchasing an additional 1,747,423 shares in the last quarter. Finally, Polen Capital Management LLC increased its stake in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS stock opened at $148.33 on Friday. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock's fifty day simple moving average is $152.32 and its 200-day simple moving average is $157.31. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $65.74 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter last year, the firm earned $1.56 earnings per share. The business's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

ZTS has been the subject of several research analyst reports. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Argus reissued a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.